1. Home
  2. Applications
  3. Cardiotoxicity Screening

Cardiotoxicity Screening

Axol’s iPSC-derived cardiomyocytes are CiPA-validated, making them the perfect model for cardiotoxicity assays.

Human Relevant Cardiotox with iPSC-Derived Cardiomyocytes

Pre-clinical cardiotoxicity testing is being transformed by CiPA-validated iPSC-derived cardiomyocytes

IN

Quality, robust human iPSC-derived cells for cardiotoxicity testing

The Comprehensive in vitro Pro-Arrhythmia Assay (CiPA) initiative was introduced to develop a new strategy for assessing cardiac safety of compounds in vitro.

Axol’s human iPSC-derived cardiomyocytes are CiPA-validated, making them a suitable model for screening compounds for cardiotoxicity.

Reach out to learn more about our iPSC-derived cardiomyocytes, and the in house services we offer to aid your R&D

    Applications

    Assay Development

    Axol’s iPSC-derived cells are robust and reproducibly made, making them the perfect tool for your assay development requirements.

    Co-Culture Models

    Axol’s iPSC-derived cells can be grown in co-culture to provide a more physiologically relevant scenario for cellular development and function.

    Axol Services

    Stem Cell Differentiation

    We provide cost-effective services to generate multiple cell types from your iPSCs. Our protocols are tailored for large scale production.

    Stem Cell Reprogramming

    Our custom reprogramming and characterization services empower you to focus on your research interests and not use up your valuable time and resources generating cells